Peramivir anhydrous
As of the edition of 20 October 2026, Peramivir anhydrous is a small molecule: marketed, first approved in 2010 (JP).
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2014
- Kind
- Small molecule
- Brand name
- Rapivab
- First approved
- 13 January 2010 (JP)
- Approvals on record
- 3 in 2 regions
- Holder of the most recent approval
- BioCryst Pharmaceuticals; 2 holders in all
- Registered trials
- 15, 5 stopped early
- Disease areas
- Infections; Lungs and airways; Ear, nose and throat; Mouth and teeth; Animal diseases; Bones, joints and muscles
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 5 | 3 | 1 | 1 |
| Phase 3 | 8 | 3 | 1 | 4 |
| Phase 4 | 1 | 1 | 0 | 0 |
| All trials | 15 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| BioCryst Pharmaceuticals | Applicant and Lead sponsor of trials | 2008 to now |
| Shionogi | Applicant | 2010 to now |